Trabectedin (T) in relapsed advanced ovarian cancer (ROC): A pooled analysis of three phase II studies

Scott McMeekin(European Institute of Oncology), C. Sessa(Vita-Salute San Raffaele University), Patricia S. Braly(European Institute of Oncology), A. Roszak(Greater Poland Cancer Center), Carolyn Krasner(European Institute of Oncology), Claudia Lebedinsky(European Institute of Oncology), Josep M. del Campo(European Institute of Oncology), Miguel Izquierdo(University of Amsterdam), Nicoletta Colombo(University of Milano-Bicocca), Tudor–Eliade Ciuleanu(Institute of Oncology Prof. Dr. Ion Chiricuta)

Journal of Clinical Oncology

June 20, 2007

10.1200/jco.2007.25.18_suppl.5579

Cited by 16

Related Papers

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

|The Lancet|2005|2.1k

ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up

|Annals of Oncology|2015|1.4k

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

|Annals of Oncology|2019|1.2k

Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

|Annals of Oncology|2013|1.1k

Randomized Phase III Study of Panitumumab With Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) Compared With FOLFIRI Alone As Second-Line Treatment in Patients With Metastatic Colorectal Cancer

|Journal of Clinical Oncology|2010|1k